None

PropThink: Management says Ariad is Well-Prepared for Ponatinib Launch

By Jake King On the heels of ponatinib's Priority Review announcement, Ariad Pharmaceuticals (NASDAQ:ARIA) reported 3Q financial results Wednesday, and on its related conference call e...

Ponatinib Wins Early FDA Nod

(MedPage Today) -- SILVER SPRING, Md. -- The FDA has approved ponatinib (Iclusig), a third-generation tyrosine kinase inhibitor, to treat two forms of drug-resistant leukemia, the agency said Friday.

ARIAD Announces Publication of Ponatinib Phase 1 Clinical Trial Results in the New England ...

Results demonstrate that ponatinib is highly active in heavily pretreated patients with CML and Ph + ALL

Ariad submits chronic myeloid leukemia treatment NDA

ARIAD Pharmaceuticals, Inc has submitted an NDA for its investigational BCR-ABL inhibitor, ponatinib, to the FDA. ARIAD is seeking US marketing approval for ponatinib in patients with resistant or int...

Ponatinib Retains Luster in Leukemia

ATLANTA (MedPage Today) -- Ponatinib, a third-generation kinase inhibitor, produced major responses in many patients with heavily pretreated drug-resistant leukemias in a pivotal phase II study report...

Ariad submits EU MAA for ponatinib and prepares to storm Europe

Ariad Pharmaceuticals has submitted its marketing authorisation application to the European Medicines Agency for ponatinib for resistant or intolerant chronic myeloid leukaemia and Philadelphia-chromo...

Ariad wins priority review for ponatinib in CML/Ph+ALL

Ariad Pharmaceuticals is expected to know the US fate of its investigational pan-BCR-ABL inhibitor ponatinib by 27 March 2013, with the FDA accepting the company's new drug application (NDA) for the...

Ariad's ponatinib gets CHMP nod for CML and Ph+AML

News in a Nutshell Ariad Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on its kinase inhibitor Iclusig (ponatinib)....

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

Fms-like tyrosine kinase (FLT3) mutations are the most frequent mutations in patients with acute myeloid leukaemia (AML) that confer a poor prognosis. Constitutively active FLT3-ITD (internal tandem d...

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

PURPOSE: Activating mutations in FGFR2 have been identified as potential therapeutic targets in endometrial cancer, typically occurring alongside genetic alterations that disrupt the mTOR pathway, suc...

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.

PURPOSE: Cardiac dysfunction, particularly QT interval prolongation, has been observed with tyrosine kinase inhibitors approved to treat chronic myeloid leukemia. This study examines the effects of po...

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mut...

Haematology: Ponatinib-the next TKI challenge.